NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases
Tuesday, 20 April 2021
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
No Comments
New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay
Thursday, 10 December 2020
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
Thursday, 11 July 2019
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway. Madison, WI – July 2019
- Published in News